Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice

[1]  Kenji Nakamura,et al.  Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis , 2000, Oncogene.

[2]  Cheryl Jorcyk,et al.  The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.

[3]  A. Roberts,et al.  Heterotopic endochondrial ossification with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-beta1 and BMP-2 expression , 1999, Oncogene.

[4]  T. Ried,et al.  Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice , 1998, Oncogene.

[5]  W. Yung,et al.  Overexpression of E2F‐1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo , 1998, Nature Medicine.

[6]  R. Kucherlapati,et al.  K-ras is an essential gene in the mouse with partial functional overlap with N-ras. , 1997, Genes & development.

[7]  J. Ward,et al.  p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. , 1996, Cancer research.

[8]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[10]  R. Lidereau,et al.  Point mutation at codon 12 of the Ki-ras gene in a primary breast carcinoma and the MDA-MB-134 human mammary carcinoma cell line. , 1990, Cancer letters.

[11]  M. Aapro,et al.  Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. , 1989, Cancer research.

[12]  D. George,et al.  Enhanced c-Ki-ras expression associated with Friend virus integration in a bone marrow-derived mouse cell line. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Slamon,et al.  Expression of p21 ras oncoproteins in human cancers. , 1986, Cancer research.

[14]  J. L. Bos,et al.  A human gastric carcinoma contains a single mutated and an amplified normal allele of the Ki-ras oncogene. , 1986, Nucleic acids research.

[15]  H. Varmus,et al.  Identification of a provirally activated c‐Ha‐ras oncogene in an avian nephroblastoma via a novel procedure: cDNA cloning of a chimaeric viral‐host transcript. , 1986, The EMBO journal.

[16]  J. Filmus,et al.  Stability of c-K-ras amplification during progression in a patient with adenocarcinoma of the ovary. , 1985, Cancer research.

[17]  J. Rhim,et al.  Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Jeffrey,et al.  Varying degrees of amplification of the N-ras oncogene in the human breast cancer cell line MCF-7. , 1985, Cancer research.

[19]  P. Seeburg,et al.  Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations , 1983, Nature.

[20]  Jeffrey E. Green,et al.  Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21 , 2001, Cancer Gene Therapy.